Diagnosis and Management of Toxoplasmosis in HIV-Infected Patients

Clinical Presentation and Diagnosis

The Centers for Disease Control and Prevention recommends that multiple bilateral ring-enhancing lesions in an HIV-positive patient with presumed low CD4 count is the classic presentation of CNS toxoplasmosis 1, 2
The most common locations for toxoplasmosis are the basal ganglia and cerebral corticomedullary junction, though cerebellar involvement is well-documented 3, 1
The subacute presentation with headache, dizziness, and mild gait ataxia over several days fits the typical clinical course of toxoplasmosis 3
Staphylococcal brain abscesses are less likely because they typically present more acutely with fever and systemic signs of infection, usually occur as complications of endocarditis, trauma, or neurosurgery, and are less commonly multiple and bilateral in distribution 1, 2
Tuberculomas are possible but less likely because they tend to be more numerous and smaller, are often associated with basilar meningitis, and the clinical presentation is usually more indolent 2
Neurocysticercosis is unlikely because lesions are typically more numerous and smaller, calcifications are common on imaging, and the patient lacks epidemiological risk factors 3, 1, 2
Hydatid cyst disease is very unlikely because it typically presents as single, large cystic lesions, lacks ring enhancement, and requires specific endemic exposure 3, 1

Brain biopsy pathology would be definitive and should demonstrate necrotizing inflammation with microglial nodules and gliosis, Toxoplasma cysts or tachyzoites on histology 2
Serum IgG antibodies define patients at risk for reactivation disease, though negative serology does not exclude the diagnosis 3, 1
MRI is more sensitive than CT and typically shows multiple T2-hyperintense, T1 ring-enhancing lesions 1, 2
CSF PCR for Toxoplasma has limited sensitivity and is not standardized, making it less reliable 3

The Centers for Disease Control and Prevention recommends that pyrimethamine plus sulfadiazine (or clindamycin if sulfa-allergic) with leucovorin supplementation is the treatment of choice for toxoplasmosis 3, 1
Trimethoprim-sulfamethoxazole is an alternative with similar efficacy and practical advantages 3
Clinical and radiological response should be evident within 10-14 days; lack of response warrants repeat biopsy 1, 2

In patients with advanced HIV infection and ring‑enhancing brain lesions, detection of EBV DNA in cerebrospinal fluid raises primary CNS lymphoma as the principal differential diagnosis (important for deciding whether tissue biopsy is needed if empiric therapy fails) 4.
If clinical improvement is not observed after empiric anti‑toxoplasma therapy, a brain tissue diagnosis is required to confirm or exclude EBV‑associated primary CNS lymphoma 4.
Cryptococcal antigen testing should be performed to exclude cryptococcal meningitis, which can also present with lymphocytic pleocytosis in this patient group 4.

When neurological deterioration occurs despite adequate anti‑toxoplasma treatment, add intravenous ganciclovir (5 mg/kg twice daily) or foscarnet (90 mg/kg twice daily) to cover potential CMV encephalitis 4.
In the same scenario, repeat lumbar puncture with quantitative CMV PCR on CSF is recommended to assess for CMV CNS involvement 4.

Continue the acute anti‑toxoplasma regimen for a minimum of six weeks before transitioning to maintenance therapy 5.
After clinical and radiological response, institute lifelong secondary prophylaxis with pyrimethamine + sulfadiazine + leucovorin to prevent relapse 5.
For patients intolerant to sulfonamides, an alternative maintenance regimen of pyrimethamine + clindamycin is recommended 5.
Discontinue secondary prophylaxis only after the CD4⁺ count has risen above 200 cells/µL and been sustained for at least six months on effective antiretroviral therapy 5.